175P - KRAS mutational status and its clinical implications in Saudi colorectal cancer patients

Date 19 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 1
Topics Colon and Rectal Cancer
Pathology/Molecular Biology
Basic Scientific Principles
Presenter Omalkhair Abulkhair
Citation Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523
Authors O.A. Abulkhair, A.S. Alqahtani, A. Gasmelseed, N. Abdelhafiz, A. Al Olayan, A. Saadeddin
  • Oncology, King Abdulaziz Medical City-Riyadh, 11426 - Riyadh/SA



This study investigates the frequency, impact of KRAS mutation and the association between clinicopathological features and KRAS status in CRC Saudi patients.


We retrospectively studied tumor samples of 221 Saudi CRC patients for KRAS status, clinicopathological characteristics and clinical outcome.


KRAS mutations were identified in 97/221 (45%) tumors. Gender, smoking history, stage at diagnosis, differentiation and lymphatic and vascular invasion were tested as potential risk predictors for KRAS status. Only gender was found to be a potential risk factor. Female compared to male gender posed a higher significant chance of mutant status (59%, P = 0.027). KRAS status did not significantly impact on clinical outcome and overall survival (OS) (median OS was not reached in both groups (P = 0.87).


This retrospective study highlights the incidence of KRAS mutations among Saudi population with CRC (45%). It is more frequently seen in female than male. This higher incidence could be attributed to ethnic differences and warrant further investigation to clarify the effect of other environmental and genetic factors. However in these patients, KRAS mutation status did not significantly impact clinical outcome or overall survival.

Clinical trial identification


All authors have declared no conflicts of interest.